Find Clinical Trials

Inclusion Criteria: * One to 5 healthcare providers * Minimum of 2 non-physician staff available at any time * Use an electronic health record (EHR) system to deliver care * Have no plans to participate in another CVD-related quality improvement initiative during the study * Willing to identify a "physician champion" or staff member to collaborate on all aspects of the intervention * Have a minimum of 200 patients on their practice panels that have hypertension that are managed by the practice * Agree to study terms including randomization, data sharing, participation in PF, and completion of surveys Exclusion Criteria: * Five or more healthcare providers * Do not have sufficient non-physician staff on board to adopt team-based care * Do not use an electronic health record (EHR) system to deliver care * Participation or planned participation in another CVD-related improvement initiative during the time of the study * Unwilling to identify a "physician champion" or staff member to collaborate on all aspects of the intervention * Less than 200 patients on their practice panel that have hypertension that are managed by the practice. * Failure to agree to study terms including randomization, data sharing, participation in PF, and completion of surveys * Primary care practices which are unable to provide patient level BP data for 6 months prior to enrolling into the study.

Main Inclusion Criteria for the Single Agent Dose Escalation and the Combination with Pembrolizumab: 1. Adults ≥ 18 years of age at the time of signing the informed consent form 2. Histologically or cytologically confirmed diagnosis of epithelial OC (high-grade serous or endometroid), TNBC, or non-squamous NSCLC. For the combination with pembrolizumab, only subjects with histologically or cytologically confirmed diagnosis of epithelial OC (high-grade serous or endometroid), non-squamous NSCLC and ductal pancreatic adenocarcinoma. 3. MSLN expression with staining intensity of ≥ 2+ as per IHC in ≥ 40% of tumor cells. Staining for MSLN expression can be performed using archival tumor tissue and is foreseen to be performed at the institution's pathology. A slice for centralized IHC assessment for validation and biomarker analysis is mandatory. 4. Patients with advanced, metastatic, or recurrent disease * after at least 1 prior systemic treatment for the primary malignancy and * who have failed treatment with, are intolerant to, or are not candidates for available therapies that are known to confer a clinical benefit to patients with these tumor entities. 5. Measurable disease according to the revised RECIST guideline version 1.1(3) 6. Patients treated in either the single agent recommended dose expansion cohort or in the combination with pembrolizumab cohort should have accessible lesions at screening for baseline and on treatment biopsies. 7. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1. 8. Negative pregnancy test at inclusion. 9. Life expectancy of at least 2 months. Main Inclusion Criteria for the Randomized study arm: 1. Female patients ≥ 18 years of age. 2. Patients must have a confirmed diagnosis of high-grade serous epithelial ovarian cancer. 3. Patients must have platinum-resistant disease: 3.1. Patients who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response (CR or PR) and then progressed between greater than 3 months and ≤ 6 months after the date of the last dose of platinum. 3.2. Patients who have received 2 or 3 lines of platinum therapy must have progressed on or within 6 months after the date of the last dose of platinum 4. Patients must have progressed radiographically on or after their most recent line of therapy. 5. Patients must be willing to provide an archival tumor tissue block or slides, or undergo procedure to obtain a new biopsy using a low risk, medically routine procedure for IHC confirmation of MSLN expression. 6. MSLN expression with staining intensity of ≥ 2+ as per IHC in ≥ 40% of tumor cells. Staining for MSLN expression can be performed using archival tumor tissue and can be done at the institution's pathology. A slice for centralized IHC assessment for validation and biomarker analysis is mandatory. 7. Patients must have at least one lesion that meets the definition of measurable disease by RECIST v1.1 (radiologically measured by the Investigator). 8. Patients must have received at least 1 but no more than 3 prior systemic lines of anticancer therapy, and for whom single-agent therapy is appropriate as the next line of treatment: * Adjuvant ± neoadjuvant considered one line of therapy * Maintenance therapy (e.g., bevacizumab, PARP inhibitors) will be considered as part of the preceding line of therapy (i.e., not counted independently) * Therapy changed due to toxicity in the absence of progression will be considered as part of the same line (i.e., not counted independently) * Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance 9. ECOG PS of 0 or 1 10. Time from prior therapy: * Systemic antineoplastic therapy (5 half-lives or 4 weeks, whichever is shorter) * Focal radiation completed at least 2 weeks prior to first dose of study drug 11. Patients must have stabilized or recovered (Grade 1 or baseline) from all prior therapy-related toxicities. 12. Major surgery must be completed at least 4 weeks prior to first dose and have recovered or stabilized from the side effects of prior surgery. 13. Patients must have adequate hematologic, liver and kidney functions 14. Patients or their legally authorized representative must be willing and able to sign the informed consent form (ICF) and to adhere to the protocol requirements. 15. Negative pregnancy test at inclusion Main Exclusion Criteria for the Single Agent Dose Escalation and the Combination with Pembrolizumab: 1. Patient has known hypersensitivity to NI-1801 or any of the constituent compounds. 2. Radiotherapy to the target lesions within 4 weeks prior to the first NI-1801 infusion. 3. Prior anti-cancer therapy including chemotherapy, hormonal therapy, and investigational agents within 2 weeks or within ≤ 5 half-lives prior to starting NI-1801 dosing (up to a maximum of 4 weeks), whichever is longer. The maximum required washout period will thus not exceed 4 weeks prior to the day of first treatment with NI-1801. Note: Low dose steroids (oral prednisone or equivalent ≤ 20 mg per day, including systemic or topic use), localized noncentral nervous system (CNS) radiotherapy of non-target lesions, and treatment with bisphosphonates and RANKL inhibitors are not criteria for exclusion. 4. Other investigational therapies must not be used, i.e., treatment within another clinical trial is not permitted, while the patient is on study. COVID-19 vaccination is allowed only starting from Cycle 2 (if not completed before study inclusion). 5. Severe cardiac dysfunction (NYHA classification III-IV). 6. Significant hepatic dysfunction (serum bilirubin ≥ 1.5 mg/dL or AST and/or ALT ≥ 2.5 times normal level), unless related to liver metastasis. 7. Patients with known human immunodeficiency virus (HIV) infection or known history or serological evidence of prior hepatitis B or C virus infection. Active SARS-COV2 infection. 8. Uncontrolled active systemic bacterial, viral, fungal, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment), or intravenous anti-infective treatment within 2 weeks prior to first dose of NI-1801. 9. Patients with concomitant active malignancy, requiring ongoing systemic treatment. 10. Patients with known CNS metastases. 11. Platelet count lower than 100 x 10\^9/L (transfusion support within 14 days before the test is not allowed). 12. Hemoglobin lower than 10.0 g/dL. Prior RBC transfusion is permitted. 13. ANC lower than 1 x 10\^9/L (the use of colony stimulating factors, G-CSF or GM-CSF, within 14 days before the test is not allowed). 14. Pregnancy and lactation. 15. History of psychiatric illness or substance abuse likely to interfere with ability to comply with protocol requirements or give informed consent. 16. Significant medical diseases or conditions, including laboratory abnormalities, as assessed by the Investigators and Sponsor, which would substantially increase the risk-benefit ratio of participating in the study. This includes, but is not limited to, acute myocardial infarction within the last 6 months, unstable angina, uncontrolled diabetes mellitus, and severely immunocompromised state, major surgery ≤ 4 weeks prior to starting NI-1801. 17. Prior treatment with a CD47, SIRPα, or MSLN targeting agent. 18. Patients in whom acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure have not resolved to Grade ≤ 1 or returned to baseline except for alopecia (any grade), anemia, and peripheral neuropathy (for the latter, recovery to Grade ≤ 2 is acceptable). 19. People who are detained through a court or administrative decision, receiving psychiatric care against their will, adults who are the subject of a legal protection order (under tutorship/curatorship), people who are unable to express their consent, and people who are subject to a legal guard

Inclusion Criteria: * Clinical diagnosis of Depression * must be willing to cooperate. Exclusion Criteria: * implanted electronic devices (e.g., pacemaker, medication pump, brain or vagus nerve stimulator, cochlear implant) * history of seizures * intracranial metal (e.g., aneurysm clip) * inability of the participant to cooperate with the Transcranial Magnetic Stimulation (TMS) session

Inclusion Criteria: * Women with a history of breast cancer treated with curative intent who have completed primary therapy (consisting of surgery with or without chemotherapy, targeted therapy, immunotherapy and/or radiation) \>= 12 months prior to registration. Concurrent trastuzumab /pertuzumab is permissible * May be receiving ongoing adjuvant endocrine therapy (with an AI or tamoxifen +/- ovarian function suppression). Patients are not required to receive these treatments to be eligible. Participants receiving adjuvant endocrine therapy prior to registration must intend to continue the same endocrine therapy for the 4 months while they are receiving protocol treatment, unless a clinically necessary change is indicated at the discretion of the patient's medical oncologist. Patients on aromatase inhibitor (AI) therapy, tamoxifen with or without ovarian function suppression therapy must have been on their current endocrine therapy regimen for at least 6 months prior to registration * Patient-reported vaginal dryness with or without dyspareunia of at least moderate severity on average, defined as \>= 4 on a 0-10-point scale that has been bothersome for \>= 3 months and for which the patient wants to undergo the study procedure * No evidence of metastatic breast cancer. Scans to assess for metastatic disease are not required for eligibility * No prior gynecologic cancer, vaginal intra-epithelial neoplasia, pelvic radiation or pelvic reconstructive surgery utilizing mesh. Patients with cervical intraepithelial neoplasia are eligible * No history of scleroderma, lupus, systemic sclerosis, mixed connective tissue disorder, undifferentiated connective tissue disorder or collagen vascular disease, dermatomyositis, polymyositis, lichen sclerosis or vulvar vestibulitis * No pelvic surgery that involved a vaginal incision within 6 months of registration. Patients who received laparoscopic BSO (Bilateral salpingooophorectomy) are eligible * No systemic estrogen or progesterone, vaginal estrogen, vaginal prasterone, ospemifene, and/or androgen therapy within 6 weeks prior to registration * No other suspected contraindications for undergoing laser therapy * No prior vaginal laser therapy at any time. Patients who would have completed any type of vaginal laser resurfacing procedure at any time prior to the start of study treatment are not eligible * No known concurrent invasive carcinoma/malignancy. Patients with carcinoma in situ are eligible. Patients with a prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible if not currently receiving treatment * Postmenopausal based on at least one of the following criteria at the time of registration: * Women 50 or older with no spontaneous regular menses \> 12 months * On ovarian suppression (i.e., gonadotrophin releasing hormone \[GNRH\] agonist/antagonist) for at least 6 months or greater, with plans to continue such treatment for at least 18 weeks * Bilateral oophorectomy * Women on AI therapy (i.e., clinically judged to be postmenopausal) * In order to complete the mandatory patient-completed measures, participants must be able to speak, read and understand English or Spanish * Age \>= 22 years * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * No medical history of: keloid formation, genital fistula, thin recto-vaginal septum (defined as a distance of \< 2 cm between the vaginal opening and the anal opening)

Inclusion Criteria: * Female, aged ≥18 and ≤70 years; * Histologically confirmed invasive breast cancer (cT2-4N0-2M0 or cT1N1-3M0 before neoadjuvant treatment); * Completed neoadjuvant treamtment and surgery (within 4 years after surgery); * Administered neoadjuvant chemotherapy (regardless of chemotherapy regimen); * ECOG 0-1 Exclusion Criteria: * Metastatic disease (Stage IV); * Female patients who are pregnancy or lactation; * Uncontrollable puncture site infection or systemic infection;

Inclusion Criteria: Patients will be included in the trial only if they meet all the following criteria: 1. Have given written informed consent prior to any trial-specific procedures 2. Are reliable, willing to be available for the duration of the trial and are willing to follow trial procedures 3. Are female and aged ≥ 18 years 4. Diagnosis of hormone receptor positive (HR+), HER2- breast cancer. Although not required as a protocol procedure, metastatic disease should be considered for biopsy whenever possible to reassess HR and HER2 status if clinically indicated. 5. To fulfill the requirement for HR+ disease, a breast cancer must express, by immunohistochemistry (IHC), at least one of the hormone receptors (estrogen receptor \[ER\], progesterone receptor \[PgR\]) as defined in the relevant American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guidelines (Hammond et al. 2010). 6. To fulfill the requirement of HER2- disease, a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression of HER2 by either IHC or in-situ hybridization (ISH) as defined in the relevant ASCO/CAP guidelines (Wolff et al. 2013). 7. Have locally advanced recurrent disease not amenable to resection or radiation therapy with curative intent or metastatic disease 8. Indication for endocrine based therapy in the metastatic setting 9. Have a performance status (PS) of ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale 10. If central nervous system (CNS) metastases are known these have to be stable (radiotherapy finished for more than 14 days ago, no required steroid medication with more than 4 mg Dexamethasone per day) 11. Pre- and postmenopausal patients are allowed. Postmenopausal is defined as no menses for 12 months without an alternative medical cause. Women of Childbearing Potential (WOCBP, defined as not postmenopausal and not surgically or congenitally sterile) whose male partners are potentially fertile (e.g. no vasectomy) must use highly effective contraception methods for the duration of the trial and for at least 3 weeks after last dose of drugs used in the trial.Women of childbearing potential must use highly effective contraception methods for two years after the last dose of fulvestrant. Highly effective birth control methods that results in a failure rate of less than 1% per year include combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner. Sexual abstinence is only considered a highly effective method if defined as refraining from heterosexual intercourse in the defined period. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the trial and the preferred and usual lifestyle of the patient. 12. No prior therapy for metastatic disease (except for first line endocrine therapy for maximal 3 months prior to start of abemaciclib therapy and if no progress occurred before study entry) 13. Previous adjuvant endocrine therapy and (neo)adjuvant chemotherapy is allowed 14. Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or ≤ Grade 2 peripheral neuropathy prior to registration. A washout period of at least 21 days is required between last chemotherapy dose and registration (provided the patient did not receive radiotherapy). 15. Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and registration. 16. One of the following as defined by the RECIST v1. 1 (see Attachment 15.5): 1. Measurable disease. At least one measurable lesion assessable using standard techniques by Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1). Tumor evaluation according to RECIST version 1.1 (based on local assessment) has to be performed within 28 days before trial registration. 2. Nonmeasurable bone-only disease (must be evaluable, but not necessarily measurable by RECIST). Nonmeasurable bone-only disease may include any of the following: blastic bone lesion, lytic bone lesions without a measurable soft tissue component, or mixed lytic-blastic bone lesions without a measurable soft tissue component. 17. The patient has adequate bone marrow and organ function evidenced by the following laboratory results: absolute neutrophil count (ANC) ≥ 1.5 × 109/L, Platelet count ≥ 100 × 109/L, Hemoglobin ≥ 8 g/dL, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.0 × ULN (≤ 3 x ULN in case of liver metastases), Total Bilirubin ≤ 1.5 × ULN (with Gilbert's syndrome max. 2 x ULN), Serum Creatinine ≤ 2.0 mg/dl or 177µmol/L, Coagulation: International Normalized Ratio (INR) ≤ 1,5 18. The patient is able to swallow oral medications 19. Willingness to use the provided CANKADO digital health application to report side effects and patient reported outcomes (The use of the CANKADO app is not mandatory for study participation, but is strongly recommended) 20. Negative pregnancy test before trial registration for women of child-bearing potential and highly effective contraception if the risk of conception exists and a negative serum pregnancy test within 7 days after the first dose of trial treatment. Pregnancy tests should be performed in premenopausal patients according to local standard Exclusion Criteria: Patients will be included in the trial only if they meet none of the following criteria: 1. Visceral crisis or life expectancy \< 6 months 2. History of hypersensitivity reactions attributed to Abemaciclib or to other components of drug formulation 3. Prior treatment with chemotherapy in the metastatic setting or endocrine therapy in the metastatic setting (except for first line endocrine therapy in metastatic or locally advanced disease for maximal 3 months prior to start of abemaciclib therapy and if no progress occurred before study entry) 4. Patient not eligible for endocrine based therapy 5. Any concurrent severe, uncontrolled systemic disease, social or psychiatric condition that might interfere with the planned treatment and with the patient's adherence to the protocol 6. The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this trial (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \[e.g. estimated creatinine clearance \<30ml/min\], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea). 7. Prior treatment with a CDK4/6 inhibitor for metastatic or locally advanced disease (first-line treatment with a CDK 4/6 inhibitor (Ribociclib/Palbociclib) in the metastatic setting is allowed only if terminated due to toxicity after max 3 months and no progression occurred before study entry. Prior treatment with a CDK 4/6 inhibitor in the neo-/adjuvant setting is allowed.) 8. 8\. Treatment with any other investigational agents within four weeks or 5 half-lives prior to trial registration, whichever is longer 9. The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. 10. Females who are pregnant or lactating 11. Legal incapacity or limited

Inclusion Criteria: 1. Histologically or cytological confirmed recurrent OMBC. 2. Age ≥18 years old. 3. OMBC defined as 1-5 metastases in a maximum of two organs confirmed by PET-CT. 4. Patients already on 1st line systemic treatment can be enrolled if repeated tumour evaluations show stable disease. 5. Patients with de novo stage IV OMBC must have a controlled primary tumour regardless of primary surgery or primary systemic treatment. 6. Patients with local recurrence and OMBC must have a controlled local recurrence. 7. ECOG/WHO 0-2. 8. Life expectancy \> 6 months. 9. Known ER, PgR and HER2 status of either primary tumour or metastasis (preferred). 10. If measurable lesions, each ≤ 5 cm. 11. Symptomatic bone metastases are allowed if ablative therapy can be delivered (femoral metastasis not allowed). 12. Adequate organ function for the planned treatment according to local guide-lines. 13. For patients with liver metastasis: * No cirrhosis or hepatitis * Hepatic function: * Total bilirubin level \< 3.0 x institutional ULN * ALT, AST, GGT, and alkaline phosphatase levels \< 3.0 x institutional ULN * Albumin \> 2.5 mg/dL * Metastasis not adjutant to stomach or small bowel. 14. For patients with abdominal metastases: adequate renal function with a calculated creatinine clearance of \> 60mL/min. 15. Toxicities from previous adjuvant therapies (excluding alopecia) must have recovered to grade 1 (defined by CTCAE 5.0). Stable grade 2 peripheral neuropathy are considered individually by the investigator. 16. Negative pregnancy test within 14 days prior to start of treatment\*. 17. If childbearing potential, willing to use an effective form of contraception\*. 18. No other malignancy during the last 5 years except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix. 19. Signed informed consent and willingness to follow the trial procedures. Exclusion Criteria: 1. \> 1 line of systemic treatment for OMBC due to previous progressing disease (previous treatment of isolated local recurrences with a 2nd adjuvant treatment not included). 2. Oligometastases in brain. 3. Malignant pleural effusion or ascites. 4. Metastasis growth that involves \> 3 vertebra and adjacent spinal cord, spine instability or neurological deficit resulting from compression, 25% spinal canal compromise or progressive neurological deficit. 5. Unable to undergo imaging by either CT scan or MRI. 6. Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment or affect patient compliance. 7. Pregnancy or breast-feeding. 8. Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ).

Inclusion Criteria: * Black/African American males, age 21 years or older with diagnosis of T2D for six months, transportation to attend program activities, under the care of a physician for diabetes, and willing to attend group delivered sessions. Exclusion Criteria: * We considered restricting eligibility to a higher-risk population of participants with A1c ≥ 8%. Preliminary data suggest that over 50% of the proposed study sample will have an A1c ≥ 8%. Focusing on all older Black men with T2D allows us to cast a wide net for secondary prevention and public health impact.

Key Inclusion Criteria: * Individuals, regardless of race and ethnic group, with previously untreated locally advanced, inoperable or metastatic triple-negative breast cancer (TNBC) * Individuals whose tumors are programmed cell death ligand 1 (PD-L1) negative at screening or individuals whose tumors are PD-L1 positive at screening if they have received an anti-PD-(L)1 inhibitor in the (neo) adjuvant setting or if they cannot be treated with a checkpoint inhibitor due to a comorbidity * Centrally confirmed TNBC and PD-L1 status on fresh or archival tissue * Individuals must have completed treatment for Stage I-III breast cancer, if indicated, and ≥ 6 months must have elapsed (with the exception of endocrine therapy) between completion of treatment with curative intent and first documented local or distant disease recurrence * Individuals presenting with de novo metastatic TNBC are eligible * Measurable disease based on computed tomography (CT) or magnetic resonance imaging (MRI) in accordance with per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. as evaluated locally * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Demonstrates adequate organ function * Male individuals and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception * Individuals with human immunodeficiency virus (HIV) must be on antiretroviral therapy (ART) and have a well-controlled HIV infection/disease Key Exclusion Criteria: * Positive serum pregnancy test or women who are lactating * Received systemic anticancer treatment within the previous 6 months or radiation therapy within 2 weeks prior to enrollment * Have not recovered from adverse events (AEs) due to a previously administered agent at the time study entry * May not be participating in a study with an investigational agent or investigational device within 4 weeks prior to randomization. Individuals participating in observational studies are eligible * Previously received topoisomerase 1 inhibitors or antibody drug conjugates containing a topoisomerase inhibitor * Active second malignancy * Active serious infection requiring antibiotics * Positive for HIV-1 or 2 with a history of Kaposi sarcoma and/or Multicentric Castleman Disease * Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Inclusion Criteria 1. Age: 18-75 years old 2. Patients with T2DM with A1c between 6.5 and 9.0 % and on stable doses of medications who are weight-bearing and self-ambulatory. 3. Own a smartphone (Apple iOS or Android OS) 4. Baseline eating period ≥12 hours/day and sufficient logging on the mCC app. 5. Women of childbearing age will be given a pregnancy test on study enrollment and asked to use contraception throughout the study. 6. Post-menopausal and women on hormone replacement therapy will be included. 7. Estimated Glomerular Filtration Rate (EGFR) \> 30mL/min/1.73m2 8. If participants are on cardiovascular medications (HMG CoA reductase inhibitors (statins), other lipid-modifying drugs, anti-hypertensives) no dose adjustments will be allowed during the study period 9. Patients on stable doses of GLP-1 receptor agonists will be included. Exclusion Criteria 10. Participants with Type1DM and T2DM who are taking insulin, sulfonylureas, or have an HbA1c \> 9 %. 11. BMI \> 50 kg/m2 12. Systolic BP greater than 160 mmHg and/or Diastolic BP greater than 110 mmHg (with or without treatment/medication) 13. LDL cholesterol greater than 200 mg/dL 14. Triglycerides greater than 500 mg/dL 15. Active tobacco or illicit drug use 16. Pregnant or breastfeeding women. 17. Currently enrolled in a weight-loss or weight-management program, 18. Currently on a special or prescribed diet for other reasons (e.g., Celiac disease), 19. The recent initiation, within the 3 preceding months prior to study enrollment, of medications designed for weight loss or with recognized appetite-suppressant effects (e.g. GLP-1 receptor agonists). Patients that are stable on such medications for at least 3 months can still be enrolled. 20. History of eating disorder(s). 21. History of surgical intervention for weight management (e) active eating disorder. 22. Chronic kidney disease with an eGFR calculated based on the Modification of Diet in Renal Disease (MDRD) equation \< 30mL/min/1.73m2 23. Treatment for active inflammatory and/or rheumatologic disease and cancer. 24. A major adverse cardiovascular event within the past 6 months such as acute coronary syndrome (ACS), percutaneous coronary intervention, coronary artery bypass graft surgery, hospitalization for congestive heart failure, stroke/transient ischemic attack (TIA). 25. History of Uncontrolled arrhythmia (i.e., rate-controlled atrial fibrillation/atrial flutter are not exclusion criteria) 26. Liver cirrhosis and/or significant alterations in liver function 27. History of (a) thyroid disease requiring dose titration of thyroid replacement medication(s) within the past 3 months (i.e., hypothyroidism on a stable dose of thyroid replacement therapy is not an exclusion), 28. Known inflammatory and/or rheumatologic disease. 29. Shift workers with variable (e.g., nocturnal) hours. 30. Caregivers for dependents requiring frequent nocturnal care/sleep interruptions. 31. More than one trip planned to travel to a time zone with greater than a 3-hour difference during study period. 32. History of major adverse cardiovascular events within the past 1 year (acute coronary syndrome (ACS), percutaneous coronary intervention, coronary artery bypass graft surgery, hospitalization for congestive heart failure, stroke/transient ischemic attack (TIA)). 33. History of thyroid disease requiring dose titration of thyroid replacement medication(s) within the past 3 months (i.e., hypothyroidism on a stable dose of thyroid replacement therapy is not an exclusion). 34. History of adrenal disease. 35. History of malignancy undergoing active treatment, except non-melanoma skin cancer. 36. Known history of type I diabetes. 37. History of stage 4 or 5 chronic kidney disease or requiring dialysis. 38. History of HIV/AIDS. 39. Uncontrolled psychiatric disorder (including history of hospitalization for psychiatric illness).

Inclusion Criteria: * Signed Informed Consent * Normal Tension Glaucoma with typical nerve fiber layer defects in red-free photographs and/or optical coherence tomography (OCT) and possible equivalent visual field defects, IOP never more than 21 mmHg, and open anterior chamber angle * Glaucoma unstable with current medication assessed by a glaucoma specialist Exclusion Criteria: * Secondary Glaucoma e.g. due to previous injury or uveitis * Exfoliation syndrome * Pigment dispersion syndrome * Previous transscleral or endoscopic cyclophotocoagulation * Previous other glaucoma surgery * Previous retinal detachment * Previous intraocular surgery like vitrectomy and other retinal surgery * Wet age-related macular degeneration * Diabetic retonopathy * Previous corneal transplant or previous refractive surgery * Fuchs' dystrophy and other abnormalities compromising corneal clarity like scars * The patient does not want to participate in the study * The patient does not speak Finnish, Swedish or English * Dementia * Only eye with vision worse than 20/200 or loss of central visual field

Inclusion Criteria: COVID-19 survivor inclusion criteria * African American * Male and female * Living in a Medically Underserved Area and/or a designated rural area of South Carolina * ≥ 18 years and above * A history of a COVID-19-associated hospitalization, ER or Urgent Care visit since March 11th, 2020 * A previous diagnosis of one or more of the following conditions: type 2 diabetes, hypertension, cardiovascular disease, chronic kidney disease, or stroke (\>3 months) -Carepartner inclusion criteria * Male and female * ≥ 18 years and above * Must live on the same property or community, preferably within a 40-mile radius of the survivor * Primarily responsible for care provision and/or care/social support in the home (i.e., is not paid for services) Exclusion Criteria: * Survivor and Carepartner exclusion criteria • Enrolled in related clinical trials

Inclusion Criteria: * Age 60 or older * Ability to read, write, and speak English * Located in Las Vegas or surrounding area * Ability to travel to UNLV campus by self or possible caregiver for regular study visits * Clinically significant symptoms of depression as evidenced by: 1) Scores \> 5 on the Geriatric Depression Scale-Short Form (GDS-SF) * Mild cognitive impairment as evidenced by: 1) Scores \> 18 and \< 25 on the Montreal Cognitive Assessment (MoCA) Exclusion Criteria: * Active suicidal ideation * History of suicide attempt(s) * Current symptoms of: 1) Psychosis; 2) Active substance use disorder * Reported history of: 1) Bipolar disorder ("manic depression"); 2) Intellectual disability * Currently in or scheduled to initiate individual psychotherapy to avoid treatment interference * Psychotropic medication permitted if dose was stable over the past 2 weeks * Currently living in an institutional setting (e.g., assisted living, inpatient, skilled nursing) * Presence of notable memory-specific cognitive deficits as evidenced by: scores \< 9 on the MoCA memory subscale (rendering it difficult to participate in and track/recall events for weekly psychotherapy)

Inclusion Criteria: * English speaking subjects * With a spectrum of BPs, ranging from those with Elevated BP through Stage 1 HTN, as defined by the 2017 ACC/AHA HTN guidelines Exclusion Criteria: * Non-English speakers * BP ≤120/80 \& ≥ 140/90 mmHg * H/o diabetes, congestive heart failure, cirrhosis of the liver, hypokalemia \& other * electrolyte disturbances * H/o kidney disease * Use of glucocorticoids * Pregnant or nursing mothers * Presence of bleeding disorders * Use of anti-platelet and anticoagulant agents such as clopidogrel, aspirin, dabigatran, rivaroxaban etc * Daily sodium intake ≥ 6000 mg/day * Presence of pacemaker or other metallic implants * Allergy to iodinated contrast * Allergy to shellfish * Claustrophobia

Inclusion Criteria: 1. Age ≥ 21 and ≤ 65 years at time of enrollment. 2. Diagnosed with T2DM with baseline: 1. Fasting plasma glucose ≥ 140 mg/dl (7.8 mmol/l) and ≤ 270 mg/dL (15 mmol/L) 2. HbA1c levels ≥ 7.0% and ≤ 9.0% (53-75 mmol/mol) 3. Triglyceride level \< 400 mg/dL (4.52 mmol/L) 4. On oral anti-hyperglycemic drug regimen of metformin. Subjects may be on additional oral anti-hyperglycemic drug of a different drug class 5. Years of T2DM ≤ 10 years 3. Diagnosed hypertension with baseline: 1. Office blood pressure of SBP of ≥ 140 mmHg and ≤ 180 mmHg and DBP ≥ 90 mmHg 2. Mean 24-hour ambulatory SBP of ≥ 130 mmHg and ≤ 170 mmHg with ≥ 75% valid readings 3. On stable oral anti-hypertension drug regimen consisting of up to a maximum of three drugs 4. BMI between 27.5 and 40 kg/m2 5. C-peptide testing: non-fasting random or stimulated C-peptide ≥ 2 ng/mL (660 pmol/L) 6. Vessel diameter of 3 mm to 6.5 mm inclusively with a minimum arterial treatable length of 20 mm in one or more of the following arteries: * Renal * Hepatic Exclusion Criteria: 1. T1DM or poorly controlled T2DM (defined as HbA1c \> 9.0% or use insulin as medication to control glucose level). 2. Office diastolic blood pressure \< 90 mmHg. 3. Current use of \> 3 hypertension medications. 4. Currently on beta blockers or alpha blockers. 5. One or more documented hyperglycemia episodes requiring hospitalization in the 180-day prior to screening date. 6. Prior evidence of hypoglycemia unawareness or serious hypoglycemia with loss of consciousness or confusion sufficient to prevent self-treatment in last 6 months. 7. BMI \> 40 kg/m2. 8. Diagnosed proliferative retinopathy or evidence of peripheral neuropathy. 9. Lack of appropriate treatment site or anatomy precluding the intervention of the target arteries (renal and hepatic artery). 10. History of prior renal or hepatic artery intervention including balloon angioplasty, stenting, etc. 11. Arterial stenosis \>50% of the normal diameter segment (diameter stenosis, compared to the angiographically normal proximal or distal segment). 12. Any abnormality or disease in one or more of the target arteries that, per the physician assessment, precludes the safe insertion of the guiding catheter (including, but not limited to, artery aneurysm, excessive tortuosity, calcification). 13. Occlusive peripheral vascular disease that would preclude percutaneous femoral access for the procedure. 14. Known or suspected secondary hypertension, such as Cushing's disease or Cushing's Syndrome, hyperaldosteronism, pheochromocytoma, thyroid and parathyroid abnormalities, history of pre-eclampsia, onset of hypertension prior to the age of 18. 15. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) for two or more days per week over the month prior to enrollment. 16. Severe or unstable cardiovascular comorbidities, such as AMI or ACS, cardiac valve stenosis, pulmonary embolism, heart failure with NYHA Class III or IV, chronic atrial fibrillation, primary pulmonary hypertension, COPD. 17. Renal transplant, history of nephrectomy or single kidney, renal tumor/cancer, known non-functioning kidney, unequal renal size (\>2 cm difference in renal length between kidneys associated with a chronic kidney disease or a deterioration of the kidney function), chronic renal deficiency with eGFR ≤ 60ml/min/1.73m2, or on chronic renal replacement therapy. 18. Prior liver transplant. 19. Any organ transplantation procedures are planned in the 365 days following Index Procedure. 20. Gastrointestinal permanent anatomic alteration surgery. 21. Any surgical procedure within 30 days prior to Index Procedure. 22. Currently taking the following medications within 90 days prior to screening and/or there is a need or anticipated need for these medications during the study: 1. Systemic Corticosteroids 2. Anticonvulsants 3. Centrally acting sympatholytics 23. Bleeding disorders, such as bleeding diathesis, thrombocytopenia, and severe anemia. 24. Use of anticoagulation therapy which cannot be discontinued from 7 days before or 14 days after the Index Procedure. 25. Any other condition(s) that would compromise the safety of the Subject or compromise study quality as judged by the investigator. 26. Significant alcohol consumption, defined as more than 2 drink units per day (equivalent to 20 g) in women and 3 drink units per day (equivalent to 30 g) in men, or inability to reliably quantify alcohol intake. 27. Active substance abuse, based on Investigator judgement, including inhaled or injected drugs, within 1 year prior to the initial screening. 28. Significant weight loss within the last 6 months (e.g., \> 10% total body weight loss). 29. Hepatic decompensation defined as the presence of any of the following: 1. Serum albumin less than 3.5 g/dL 2. International normalization ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants) 3. Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome 4. History of esophageal varices, ascites, or hepatic encephalopathy 30. ALT or AST greater than 200 U/L. 31. Diagnosis of liver cirrhosis. 32. Chronic liver or biliary disease of the following etiology: 1. History or diagnosis of Hepatitis B 2. History or diagnosis of Hepatitis C 3. History or diagnosis of current active autoimmune hepatitis 4. History or diagnosis of primary biliary cholangitis 5. History or diagnosis of primary sclerosing cholangitis 6. History or diagnosis of Wilson's disease 7. History or diagnosis of alpha-1-antitrypsin deficiency 8. History or diagnosis of hemochromatosis 9. History or diagnosis of drug-induced liver disease, as defined on the basis of typical exposure and history. 10. Known bile duct obstruction. 11. Suspected or proven liver cancer 33. History of acute or chronic pancreatitis. 34. Human immunodeficiency virus (HIV). 35. Subjects with a history of adverse reaction to heparin or heparin induced thrombocytopenia (HIT). 36. Systemic infection that the investigator judges would pose unacceptable procedural risks to the subject. 37. Known hypersensitivity to contrast media, nickel and ethanol that cannot be adequately pre-medicated. 38. Subject is depressed or on antidepressants. 39. Pregnancy or breastfeeding or plan to get pregnant in next 12 months. 40. Life expectancy of less than 5 years. 41. Unwilling or unable to comply with the follow-up study requirements. 42. Lacking capacity to provide informed consent. 43. Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety. 44. Currently participation in another pre-market drug or medical device clinical study

Inclusion Criteria: * Newly diagnosed or previously diagnosed patients with PH. * Documentation of mean pulmonary arterial pressure (mPAP) \>20 mm Hg by right heart catheterization, performed at any time prior to study enrollment. Exclusion Criteria: * Have not had documentation of hemodynamic criteria for PH by right heart catheterization at some time preceding study entry and following development of symptoms associated with PH. * Do not meet the required hemodynamic criteria for entry into the study.

Inclusion Criteria: * American Society of Anesthesiologists (ASA) physical status I-III * Body mass index (BMI) less than 40 kg/m2 * Scheduled to undergo robotic-assisted radical laparoscopic nephrectomy or prostatectomy. Exclusion Criteria: * Patients with a diagnosis of chronic obstructive pulmonary disorder (COPD), severe neurological, cardiopulmonary, psychiatric, or untreated thyroid disorder * Chronic pain condition that is being treated with opioids * Patients with a hematocrit lower than 30% at the end of surgery, or those with an excessive blood loss, requiring transfusion of blood products during surgery.

Inclusion Criteria: * Age 21 years or older * clinical diagnosis of type 2 diabetes * HbA1c of 9 or higher at screening visit * screen positive for food insecurity using food insecurity risk tool * ability to communicate in English Exclusion Criteria: * mental confusion on interview suggesting significant dementia * participation in other diabetes clinical trial * alcohol or drug abuse/dependency based on CAGE screening tool * active psychosis or acute mental disorder * life expectancy of less than 6 months

Inclusion Criteria: 1. Are 21 years of age or older. 2. Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam). 3. Have the ability to understand and sign an informed consent. 4. Have been diagnosed with POAG (cohort 2). Exclusion Criteria: 1. Are under 21 years of age. 2. Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity). 3. Have visual correction outside of the range +4 diopters (D) to -8 D. 4. Have a history of adverse reaction to mydriatic drops. 5. Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG). 6. Do not meet the criteria for POAG as defined by the American Academy of Ophthalmology Practice Patterns (cohort 2) 7. Have any health conditions that would contraindicate oxygen supplementation, including chronic obstructive pulmonary disease (COPD), emphysema, asthma, or any other obstructive or restrictive lung disease (RBF experiment participants only). 8. Have a dependency on oxygen support or a baseline oxygen saturation \<95% (RBF experiment participants only). 9. Have tested positive for COVID-19 at initial enrollment or have acute or chronic photophobia as a result of contraction. 10. Are working under the direct supervision of Dr. Hammer.

Inclusion Criteria: * mood, anxiety, or anhedonia symptoms that affect functioning; fluent in English; able to see computer display; able to perform simple computer games. Exclusion Criteria: * history of seizure disorder, stroke, or head injury with more than 10 minutes of unconsciousness; hormone disorder; electroconvulsive therapy within 5 years; history of chemotherapy for cancer; current pregnancy; contraindications to MRI